Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Varicella Clear all
Completed Phase 2 Interventional Results available

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

NCT00851786
View directory record Official record
Conditions
Herpes Zoster, HIV Infections
Interventions
ZOSTAVAX, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 20, 2026, 1:51 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
View directory record Official record
Conditions
Chickenpox
Interventions
Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

ZOSTAVAX® in Renal Transplant Patients

NCT01137669
View directory record Official record
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352
View directory record Official record
Conditions
VZV Infection After Bone Marrow Transplantation
Interventions
Acyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

NCT02723773
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
7,539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 20, 2026, 1:51 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800
View directory record Official record
Conditions
Herpes Zoster
Interventions
mRNA-1468, Placebo, Shingrix
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
19
States / cities
Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 20, 2026, 1:51 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

NCT06068608
View directory record Official record
Conditions
Varicella
Interventions
TNM005, Placebo, VariZIG
Drug
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344
View directory record Official record
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

NCT04398706
View directory record Official record
Conditions
Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions
Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 15 Months
Enrollment
852 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
49
States / cities
Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Early Phase 1 Interventional Results available

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions
Shingrix vaccine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Zostavax Vaccination in Rheumatoid Arthritis

NCT01506661
View directory record Official record
Conditions
Rheumatoid Arthritis, Varicella Zoster
Interventions
Zostavax (varicella zoster virus) vaccine
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 20, 2026, 1:51 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Pregabalin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia

NCT00478179
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
Transdermal/Patch (Bupivacaine TTS [Eladur™])
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

NCT01132729
View directory record Official record
Conditions
Herpes Zoster, Shingles, Genital Herpes
Interventions
Valacyclovir Hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 20, 2026, 1:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to Varicella Vaccination in Children With Atopic Dermatitis

NCT00406081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 36 Months
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 20, 2026, 1:51 AM EDT
Active, not recruiting No phase listed Observational

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

NCT05811754
View directory record Official record
Conditions
Herpes Zoster
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Canton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 20, 2026, 1:51 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 20, 2026, 1:51 AM EDT